cefepime + dexamethasone + meropenem + methylprednisolone + piperacillin + tazobactam + vancomycin

This is a combination regimen consisting of seven drugs commonly used in critical care and severe infection settings. The components are:

• Cefepime: A fourth-generation cephalosporin antibiotic with broad-spectrum activity against Gram-positive and Gram-negative bacteria, including Pseudomonas aeruginosa. It works by inhibiting bacterial cell wall synthesis.
• Dexamethasone and Methylprednisolone: Synthetic glucocorticoid corticosteroids that act as anti-inflammatory and immunosuppressive agents by binding to the glucocorticoid receptor, modulating gene expression, and suppressing pro-inflammatory cytokines.
• Meropenem: A carbapenem-class beta-lactam antibiotic with very broad-spectrum antibacterial activity, including many multidrug-resistant organisms. It inhibits bacterial cell wall synthesis.
• Piperacillin + Tazobactam: A combination of an extended-spectrum penicillin (piperacillin) that inhibits bacterial cell wall synthesis, plus a beta-lactamase inhibitor (tazobactam) that protects piperacillin from enzymatic degradation. This combination is used for serious infections caused by susceptible organisms.
• Vancomycin: A glycopeptide antibiotic effective primarily against Gram-positive bacteria; it inhibits cell wall biosynthesis.

This multi-drug regimen may be used empirically in critically ill patients or those with suspected or confirmed severe polymicrobial infections, especially when multidrug-resistant pathogens are a concern.